Biotechnology

Samsung Biologics holds 11th Annual General Meeting of Shareholders

INCHEON, South Korea, March 28, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), hosted its 11th Annual General Meeting of Shareholders (AGM)today. Five matters were presented and approved unanimously at this ...

2022-03-29 09:42 2665

Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Growth with an Increase of 68.7%

Financial Highlights of the year ended December 31, 2021: * Revenue amounted to RMB2,104.1 million, representing a year-on-year (YoY) increase of 201.9% * Gross profit amounted to RMB651.0 million, representing a YoY increase of 113.5% * Adjusted Non-IFRS net profit amounted to RMB352.5 mil...

2022-03-29 00:49 3399

Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment

SYDNEY, March 28, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that the diagnostic 64Cu SAR-bisPSMA trial (COBRA NCT05249127 <...

2022-03-28 21:06 2399

At the 2022 AAD Annual Meeting, Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma

* Early results showed 2 laBCC (locally advanced Basal Cell Carcinoma) subjects out of 10 experienced a Partial Response (30% decrease in tumor size) at week #24. * The first biopsy analysis in the laBCC subject showed a more than 90% decrease of GLI-1 expression at week #8 (GLl-1 is involved...

2022-03-28 19:00 2444

CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China

SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that CT041, an autologous CAR T-cell product candidate against...

2022-03-23 20:50 2418

InnoCare Releases 2021 Annual Results and Business Highlights

BEIJING, March 22, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 annual results as of31 December 2021. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "We are delighted ...

2022-03-23 08:08 3819

VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease

SHANGHAI, March 22, 2022 /PRNewswire/ -- VivaVision Biotech, Inc. (VivaVision), an ophthalmic pharmaceutical developer focusing on discovery and development of innovative therapies for ocular diseases, today announced positive topline results from a Phase 2 clinical study of VVN001 in patients wi...

2022-03-23 08:00 2386

WuXi Biologics Achieved Record Growth and Profitability in 2021

Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9 Million Net Profit Grew by 107.3% Y-o-Y to RMB3,508.6 Million Adjusted Net Profit Rose by 100.3% to RMB3,435.9 Million Total Backlog Grew 20.1% to ...

2022-03-23 00:38 3682

INDICAID COVID-19 Rapid Antigen At-Home Test Receives FDA Emergency Use Authorization (EUA) for Over-the-Counter (OTC), Asymptomatic, Non- Prescription Use

GARDEN GROVE, Calif., March 22, 2022 /PRNewswire/ -- PHASE Scientific International, LTD  (PHASE Scientific), a high-growth biotech company founded by bioengineers fromUCLA, announces that its INDICAID® COVID-19 Rapid Antigen At-Home Test (INDICAID® OTC) recei...

2022-03-23 00:00 2549

Jacobio Announces Annual Results of 2021, R&D Investment Increases 83%

BEIJING and SHANGHAI and BOSTON, March 22, 2022 /PRNewswire/ -- Jacobio Announced its 2021 annual results on 22 March. As a clinical-stage biotech company, Jacobio's revenue wasRMB152 million, which was generated from an out-licensing deal. Its R&D investment wasRMB421 million, showing an increas...

2022-03-22 22:50 2879

IFF to Showcase Renewable Industrial Solutions and Polymer Portfolio at American Coatings Show

WILMINGTON, Del., March 22, 2022 /PRNewswire/ -- IFF's Industrial Solutions will bring its deep technical expertise, commitment to quality and broad portfolio of renewable polymers to theAmerican Coatings Show (ACS) for the first time on April 5-7.

2022-03-22 21:00 2678

NIBIOHN Identifies Tissue-specific Exosome Marker Candidates from Blood

OSAKA, Japan, March 22, 2022 /PRNewswire/ -- The National Institutes of Biomedical Innovation, Health and Nutrition (hereinafter NIBIOHN) based in Ibaraki-shi, Osaka Prefecture, has successfully catalogued more than 4,000 proteins contained in exosomes in healthy human blood (serum and plasma). Us...

2022-03-22 14:00 1725

OBiO Technology Goes Public on Shanghai Stock Exchange Today

SHANGHAI, March 22, 2022 /PRNewswire/ -- On March 22, 2022, OBiO Technology ( Shanghai) Corp., Ltd. ("OBiO" or "the Company"), has completed its initial public offering ("IPO") process and started trading on the Shanghai Stock Exchange's Sci-Tech innovation board (SSE, code: 688238). Founded in 2...

2022-03-22 13:00 3520

Transnetyx Announces Acquisition of a-tune

MEMPHIS, Tenn., March 22, 2022 /PRNewswire/ -- Transnetyx, a global leader in outsourced genetic services, announced the acquisition of a-tune, a best-in-class software for animal research and compliance. This acquisition allows Transnetyx to partner with a-tune to further streamline animal resea...

2022-03-22 04:30 2555

Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain

SAN DIEGO, March 21, 2022 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs, announced successful results in its Phase IIb study of its perioperative long-acting anal...

2022-03-22 00:00 2195

BIOKANGTAI Signs a Cooperation Agreement with the Largest Importer of Parenteral Products in Philippines

SHENZHEN, China, March 21, 2022 /PRNewswire/ -- On March 17, 2022, Shenzhen Kangtai Biological Products Co., Ltd signed a framework agreement with Phil.PharmaWealth Inc., the largest importer of Parenteral Products in Philippines, and both parties reached an agreement on jointly promoting the reg...

2022-03-21 22:22 2540

ABclonal Technology Joins YCharOS Industry Advisory Committee to Tackle Reproducibility Crisis in Biomedical Research

BOSTON, March 21, 2022 /PRNewswire/ -- ABclonal Technology, a rapidly growing life science research and diagnostic reagents manufacturer, today announced it has joined the Industry Advisory Committee (IAC) at YCharOS Inc., an open science company with the mission of characterizing commercially av...

2022-03-21 20:15 2234

RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics

SEOUL, South Korea, March 21, 2022 /PRNewswire/ -- RNAGene Inc., a South Korean biotech which specializes in the development of mRNA (messenger ribonucleic acid)-based therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a c...

2022-03-21 20:00 2536

KAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETING

SYDNEY, March 21, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce upcoming presentations at two international conferences. American Association of Cancer Research Annual Scientific Meeting ...

2022-03-21 20:00 3373

Nuance Pharma Announces License and Supply Agreement with Bavarian Nordic on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian Markets

* Bavarian Nordic to receive up to USD 225 million in upfront and milestone payments in addition to tiered, double-digit royalties * Nuance Pharma obtains rights to commercialize MVA-BN® RSV in Chinese Mainland,Hong Kong, Macau, Taiwan, South Korea and Southeast Asia and will be responsible f...

2022-03-21 16:20 2073
1 ... 141142143144145146147 ... 165

Week's Top Stories